Markets

Bayer to Buy Prophyta - Analyst Blog

A generic image of a pen on paper
Credit: Shutterstock photo

Bayer AG's ( BAYRY ) Bayer CropScience recently signed an agreement to acquire Prophyta GmbH which develops, produces and markets biological products, processes and services for integrated crop protection.

Headquartered at Malchow on the island of Poel, Prophyta manufactures its products at Wismar, Germany.

Prophyta's key product is Contans which is a biological plant protection product almost like a pesticide.

The acquisition seems a strategic fit for the company as it complements the existing portfolio and will enable Bayer to offer an integrated crop solutions based on high-value seeds, innovative crop protection solutions and customized services.

The financial terms of the deal were not disclosed. Bayer CropScience expects to close the acquisition in a few weeks. In addition, the acquisition will enable Bayer CropScience to further leverage its technology platform acquired through Athenix Corporation and AgraQuest.

We note that Bayer has been quite active on the acquisition front lately. In Aug, the CropScience unit of the company acquired AgraQuest, Inc., formerly a global supplier of innovative biological pest management solutions, for $425 million (approximately €340 million) in addition to milestone payments.

The acquisition has boosted Bayer's fruits and vegetables business while building a strong technology platform based on "green" products.

More recently, the HealthCare unit of Bayer AG received necessary regulatory approval from the Federal Trade Commission to complete its acquisition of Teva Pharmaceutical Industries Limited's ( TEVA ) animal health unit in the US.

In Sep 2012, Bayer had announced that in a bid to diversify its business and expand its animal health business, it inked a deal with Teva to buy its animal health unit.

As per the deal, Bayer will be paying $145 million, including an upfront payment of $60 million along with a total of $85 million in milestone payments on the successful and timely achievement of manufacturing and sales targets. The deal will also give Bayer access to Teva's 300-employee manufacturing site at St. Joseph.

We view the acquisitions as positive and reiterate our Neutral recommendation on Bayer which carries a Zacks Rank #3 (Hold). Right now, Novartis AG ( NVS ) looks attractive with a Zacks Rank #2 (Buy).

BAYER A G -ADR (BAYRY): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

TEVA PHARM ADR (TEVA): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

TEVA BAYRY NVS

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More